Flavonoid Composition for Reducing IL-6 and MCP-1 Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective solutions for reducing IL-6 and MCP-1 levels and addressing inflammation, metabolic disorders, and oxidative stress, which are associated with various diseases such as autoimmune diseases, cardiovascular diseases, and cancer.
Innovation Solution
A composition comprising at least 10% eriocitrin, potentially combined with other flavonoids like neoeriocitrin, eriodictyol, hesperidin, and omega-3 fatty acids, which acts as a potent inhibitor of NF-kB and exhibits strong antioxidant properties, is administered to treat conditions associated with elevated IL-6 or MCP-1 levels and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for reducing IL-6 and MCP-1 levels, then existing therapeutic options are limited, but treatment effectiveness is insufficient
Solution Approach 1:
The patent employs a composite flavonoid composition containing multiple specific flavonoids (eriodictyol, eriocitrin, neoeriocitrin, hesperidin, eriodictyol glucoside) in defined ratios. This composite approach synergistically combines the anti-inflammatory and antioxidant properties of individual flavonoids to achieve superior reduction of IL-6 and MCP-1 levels compared to single compounds or conventional treatments.
Solution Approach 2:
The invention optimizes the concentration parameters of each flavonoid component within specific ranges (eriodictyol: 5-50 μM, eriocitrin: 10-100 μM, neoeriocitrin: 5-30 μM, hesperidin: 10-50 μM, eriodictyol glucoside: 5-20 μM) to maximize therapeutic effectiveness while minimizing side effects, thereby improving treatment reliability across different disease conditions.
2Object-generated harmful factors
If inflammation is inhibited by blocking NF-kB, then proinflammatory cytokine production is reduced, but achieving sufficient inhibition requires potent compounds
Solution Approach 1:
The patent merges multiple flavonoid compounds that individually exhibit NF-kB inhibitory activity into a single composition. The combination of eriodictyol, eriocitrin, neoeriocitrin, hesperidin, and eriodictyol glucoside acts synergistically to enhance NF-kB inhibition strength, achieving greater potency than any single flavonoid alone while reducing proinflammatory cytokine production.
3Reliability
If flavonoids are used for their anti-inflammatory properties, then health benefits are achieved, but specific compositions with optimized efficacy are needed
Solution Approach 1:
The patent defines specific concentration ranges for each flavonoid component to optimize anti-inflammatory efficacy. By establishing precise parameter ranges (e.g., eriocitrin: 10-100 μM, hesperidin: 10-50 μM), the invention ensures reliable health benefits while providing clear formulation guidelines that balance effectiveness with manufacturability.
Solution Approach 2:
The flavonoid composition serves multiple therapeutic functions simultaneously: it inhibits NF-kB signaling, reduces IL-6 production, decreases MCP-1 levels, and provides antioxidant protection. This multi-functionality enhances overall health benefit efficacy while using a single composition formulation, thereby managing complexity efficiently.
Data Source
AI summary
This invention relates to a flavonoid composition that includes eriocitrin. The flavonoid may be included in a complex with other bioflavonoids. The composition may also include neoeriocitrin. This invention also relates to methods of using the composition, including for reducing IL-6 or MCP-1 treating inflammation, and treating symptoms of metabolic syndrome.